Telix Pharmaceuticals Limited (ASX: TLX) under health care sector is engaged into the commercializing and development of molecularly targeted radiation (MTR) products for the treatment of cancer. It is based out of Flemington road, North Melbourne, Australia. The company’s incorporation year was 2017 and is categorized as a bio-pharmaceutical company. Products such as TLX-250, TLX-591 and TLX-101 are included in company’s MTR range.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK